Pluvicto is a new treatment that has been approved by the FDA for men battling with benign and metastasizing prostate cancer. This treatment is conducted with the help of intravenous infusion which targets at destroying tiny tumours that otherwise cannot be scrutinised using conventional methods. Only patients who have already undergone anticancer therapies qualify for the new treatment. Pluvicto employs a specialised scanning technology named positron-emission tomography because it explicates the PSMA-positive tumours present in 80% of individuals suffering from prostate cancer.
Read More from HarvardHealthPublishing